Biogen
Clinical trials sponsored by Biogen, explained in plain language.
A biotechnology company focused on neurological diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New lupus drug shows promise in major trial Results expected Sep 2026 (estimated)
- New lupus drug shows promise in major trial Results expected Sep 2026 (estimated)
- New hope for lupus skin lesions: drug trial targets stubborn cases Results expected Oct 2026 (estimated)
- MS drug shot study tracks immune reactions Results expected Oct 2026 (estimated)
- New drug could save transplanted kidneys from rejection Results expected Dec 2026 (estimated)
-
New MS drug trial for japanese patients shows promise but study stopped early
Disease control Stopped earlyThis study tested the drug natalizumab in 21 Japanese adults with relapsing-remitting multiple sclerosis (MS). The goal was to see if injections under the skin every 4 weeks could reduce new brain lesions over 24 weeks, and to check safety for up to 48 weeks. The study was termin…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
ALS drug trial halted: what happened with BIIB105?
Disease control Stopped earlyThis study tested an experimental drug called BIIB105 in adults with ALS, a progressive nerve disease. The trial had two parts: a 6-month placebo-controlled phase and a 3-year open-label extension where everyone received the drug. The goal was to check safety, how the body proces…
Phase 1/2 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC